Cite
APA Citation
Domenyuk, V., Liu, X., Magee, D., Gatalica, Z., Stark, A., Kennedy, P., Rosenow, M., Barker, A., Berry, D., Poste, G., Halbert, D., Hart, C., Famulok, M., Mayer, G., Korn, M., Miglarese, M., & Spetzler, D. (n.d.). p-132Poly-Ligand Profiling differentiates pancreatic cancer patients according to treatment benefit from gemcitabine+placebo versus gemcitabine+evofosfamide and identifies candidate targets. Annals of oncology, 29, . http://access.bl.uk/ark:/81055/vdc_100095506270.0x00002b